# Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Canonical URL: https://biopharmsignal.com/news/TCMD/tactile-medical-to-present-at-the-william-blair-46th-annual-growth-stock-conference
Ticker: TCMD
Company: Tactile Systems Technology, Inc.
Source: Tactile Systems Technology, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.tactilemedical.com
## Summary

The Investor Relations website contains information about Tactile Systems Technology, Inc. 's business for stockholders, potential investors, and financial analysts.

## Article Body
MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the William Blair 46th Annual Growth Stock Conference, which is being held at the Loews Hotel in Chicago, IL, from June 2-4, 2026. Management will present on Tuesday, June 2, at 9:20 a.m. Central Time.

A live audio webcast of the presentation will be accessible under the “Events & Webcasts” section of the Company's investor relations website at http://investors.tactilemedical.com . An archive of the webcast will be available for replay following the conference.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries: Sam Bentzinger Gilmartin Group [email protected]

Source: Tactile Systems Technology, Inc.
## Recent Company News
- 2026-07-13 12:00 EST — [Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients](https://biopharmsignal.com/news/TCMD/tactile-medical-enters-exclusive-u-s-distribution-agreement-with-elastimed-for-i-116aea64) — Source: Tactile Systems Technology, Inc.
- 2026-06-25 13:46 EST — [Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy](https://biopharmsignal.com/news/TCMD/tactile-medical-launches-next-generation-afflovestr-airway-clearance-therapy) — Source: Tactile Systems Technology, Inc.
- 2026-06-25 13:46 EST — [Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference](https://biopharmsignal.com/news/TCMD/tactile-medical-to-present-at-the-william-blair-46th-annual-growth-stock-conference) — Source: Tactile Systems Technology, Inc.
- 2026-06-25 13:46 EST — [Tactile Medical to Release Third Quarter of Fiscal Year 2025 Financial Results on November 3, 2025](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-third-quarter-of-fiscal-year-2025-financial-results-on-november-3-2025) — Source: Tactile Systems Technology, Inc.
- 2026-06-25 13:46 EST — [Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch® Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema](https://biopharmsignal.com/news/TCMD/landmark-study-demonstrates-sustained-clinical-benefits-of-flexitouchr-plus-as-first-line-therapy-in-treating-head-and-neck-cancer-related-lymphedema) — Source: Tactile Systems Technology, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)